Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy by Adviti Naik (673163)

“…We investigated whether LDHC is involved in regulating genomic stability and whether it could be targeted to affect tumor cellular fitness. Silencing LDHC in four breast cancer cell lines significantly increased the presence of giant cells, nuclear aberrations, DNA damage, and apoptosis. …”

In Vitro Cell Work of Two Types of Targeted Nanoparticles with Ultrasound Triggering by Abuwatfa, Waad Hussein

Get full text

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting by Belal Chaudhary (19738021)

“…In this context, immunosuppressive cells, including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), have come under intense investigation for their proposed roles in suppressing tumor-specific immune responses and establishing an immunosuppressive tumor microenvironment, thus enabling tumor immune evasion. …”

Investigating The Efficacy of Ruxolitinib and CHIR-99021 in Targeting Pediatric Neuroblastoma Stem Cells by Al Sayyed, Fatima

“…Western blot analysis showed significant decrease in stem cell markers SOX-2 and Oct-4, and tumorigenic protein HMGA1, whereas it showed significant increase in apoptotic markers cleaved PARP and cleaved caspase-3. …”
Get full text
Get full text
Get full text

Boron doped silver-copper alloy nanoparticle targeting intracellular S. aureus in bone cells by Tahir Abdulrehman (8697696)

FoxP3⁺ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets by Reem Saleh (3513056)

“…Overall, understanding the prognostic significance of FoxP3⁺ Tregs in various cancers and their contribution to therapy resistance could help in the development of more effective targeted therapeutic strategies to enhance the clinical outcomes in cancer patients.…”

Targeting the MAP kinase pathway in astrocytoma cells using a recombinant anthrax lethal toxin as a way to inhibit cell motility and invasion by Al-Dimassi, Saleh

“…In many cell lines, the use of MAPK-targeted drugs proved to be a potential method to inhibit cancer cell motility. …”
Get full text
Get full text
Get full text
Get full text

F-box proteins in cancer stemness: An emerging prognostic and therapeutic target by Abdul Q. Khan (14153247)

“…<p dir="ltr">Cancer is a complex heterogenic disease with significant therapeutic challenges. The presence of cancer stem cells (CSCs) in cancer tissue orchestrates tumor growth, progression, and metastasis, the tumor heterogeneity, disease relapse, and therapeutic resistance. …”

Targeting solid tumor cells with novel photosensitive ruthenium-based metal-organic compounds. (c2016) by Farhat, Stephanie Roy

Get full text
Get full text
Get full text

Targeting Breast Cancer Using Hyaluronic Acid-Conjugated Liposomes Triggered with Ultrasound by Ben-Daya, Mohamed

“…These modifications allow nannocarriers to achieve greater targeting specificity through binding to specific receptors overexpressed on the surface of the tumor cells. …”
Get full text

Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report by Maysaloun Merhi (4246147)

“…<p dir="ltr">Targeting the programmed cell death protein-1 (PD-1)/PD-1 ligand (PD-L1) pathway has been shown to enhance T cell-mediated antitumor immunity. …”

Neosetophomone B induces apoptosis in multiple myeloma cells via targeting of AKT/SKP2 signaling pathway by Shilpa Kuttikrishnan (3520079)

“…<p dir="ltr">Multiple myeloma (MM) is a hematologic malignancy associated with malignant plasma cell proliferation in the bone marrow. Despite the available treatments, drug resistance and adverse side effects pose significant challenges, underscoring the need for alternative therapeutic strategies. …”

Targeting acute myeloid leukemia cells with novel photosensitive ruthenium-based metal-organic compounds. (c2015) by Azar, Daniel Fadi

“…Prognosis of patients diagnosed with AML remains low in all age groups, and most currently approved therapies against AML have serious side-effects and limited potency, necessitating the development of alternative, more potent approaches that could specifically target cancerous cells. Promising results have been reported in the field of Metallomics, in which various cancers have been targeted by compounds formed of different ligands conjugated to a metal core, one of which being ruthenium (Ru). …”
Get full text
Get full text

Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways by Hadeel Kheraldine (14231609)

“…</p><h3>Methods</h3><p dir="ltr">Herein, we investigated the impact of DA and PD-L1 inhibitor (BMS-202) combination on HER2-positive breast cancer cell lines, SKBR3 and ZR75.</p><h3>Results</h3><p dir="ltr">Our data reveal that the combination significantly inhibits cell viability of both cancer cell lines as compared to monotreatment. …”

Sestrin2 as a Novel Biomarker and Therapeutic Target for Various Diseases by Mazhar Pasha (11197767)

“…Sestrin2 also plays a pivotal role in metabolic regulation through activation of the key energy sensor AMP-dependent protein kinase (AMPK) and inhibition of mammalian target of rapamycin complex 1 (mTORC1). Other downstream effects of Sestrins include autophagy activation, antiapoptotic effects in normal cells, and proapoptotic effects in cancer cells. …”

Synergistic Effects of Nanomedicine Targeting TNFR2 and DNA Demethylation Inhibitor—An Opportunity for Cancer Treatment by Mohammad A. I. Al-Hatamleh (11564929)

“…</p><h2>Other Information</h2><p dir="ltr">Published in: Cells<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/cells9010033" target="_blank">https://dx.doi.org/10.3390/cells9010033</a></p>…”

Evidence and gaps in clinical outcomes of novel pharmacologic therapies for sickle cell disease: A systematic literature review highlighting insights from clinical trials and real-... by Mohamed Yassin (4166515)

“…<p>This systematic review aims to summarise the clinical outcomes of l-glutamine, crizanlizumab, and voxelotor in the treatment of sickle cell disease (SCD) based on clinical trials and real-world data and to identify any gaps in the observations. …”

Long non-coding RNA MALAT1 promotes steatosis in HepG2 cells by modulating target gene expression in presence of Exendin-4 by Olfa Khalifa (10914452)

“…Moreover, MALAT1 knockdown dramatically suppressed oleic-induced lipid accumulation in HepG2 cells. Interestingly, knocking down MALAT1 significantly reduces the expression of CD36 in steatosis HepG2 cells in the presence of Ex-4. …”

Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy by Remy Thomas (702843)

“…Analysis of HLA-A*0201 responses revealed a significant T cell activation after stimulation with peptide pools 2 (PP2) and 8 (PP8). …”

Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance by Gh Rasool Bhat (13038132)

“…These processes are pivotal in the development and progression of tumors, contributing to the multifaceted nature of cancer and the challenges associated with its treatment. Despite significant advancements in targeted therapies, cancer cell adaptability and subsequent therapy-induced resistance remain persistent obstacles in achieving consistent, successful cancer treatment outcomes. …”